Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for hematological malignancies. However, graft-versus-host disease (GVHD) and relapse after allo-HSCT remain major impediments to the success of allo-HSCT. Chimeric antigen receptors (CARs) direct tumor cell recognition of adoptively transferred T cells1,2,3,4,5. CD19 is an attractive CAR target, which is expressed in most B cell malignancies, as well as in healthy B cells6,7. Clinical trials using autologous CD19-targeted T cells have shown remarkable promise in various B cell malignancies8,9,10,11,12,13,14,15. However, the use of allogeneic CAR T cells poses a concern in that it may increase risk of the occurrence of GVHD, although this has not been reported in selected patients infused with donor-derived CD19 CAR T cells after allo-HSCT16,17. To understand the mechanism whereby allogeneic CD19 CAR T cells may mediate anti-lymphoma activity without causing a significant increase in the incidence of GVHD, we studied donor-derived CD19 CAR T cells in allo-HSCT and lymphoma models in mice. We demonstrate that alloreactive T cells expressing CD28-costimulated CD19 CARs experience enhanced stimulation, resulting in the progressive loss of both their effector function and proliferative potential, clonal deletion, and significantly decreased occurrence of GVHD. Concurrently, the other CAR T cells that were present in bulk donor T cell populations retained their anti-lymphoma activity in accordance with the requirement that both the T cell receptor (TCR) and CAR be engaged to accelerate T cell exhaustion. In contrast, first-generation and 4-1BB-costimulated CAR T cells increased the occurrence of GVHD. These findings could explain the reduced risk of GVHD occurring with cumulative TCR and CAR signaling.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: m1928z T cells eliminate CD19-expressing lymphoma cells while exerting significantly less GVHD activity.
Figure 2: Allogeneic m1928z T cells mediate persistent B cell hypoplasia.
Figure 3: Allogeneic m1928z T cells exhibit decreased alloreactive proliferation and GVHD target organ infiltration.
Figure 4: Alloreactive m1928z T cells are hyperactive and exhausted, and they undergo deletion.

Accession codes

Primary accessions

Gene Expression Omnibus

References

  1. Ho, W.Y., Blattman, J.N., Dossett, M.L., Yee, C. & Greenberg, P.D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3, 431–437 (2003).

    CAS  PubMed  Google Scholar 

  2. Sadelain, M., Rivière, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35–45 (2003).

    CAS  PubMed  Google Scholar 

  3. Gill, S. & June, C.H. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 263, 68–89 (2015).

    CAS  PubMed  Google Scholar 

  4. Sadelain, M., Brentjens, R. & Rivière, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388–398 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. James, S.E. et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 114, 5454–5463 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Brentjens, R.J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279–286 (2003).

    CAS  PubMed  Google Scholar 

  7. Sadelain, M. CAR therapy: the CD19 paradigm. J. Clin. Invest. 125, 3392–3400 (2015).

    PubMed  PubMed Central  Google Scholar 

  8. Kochenderfer, J.N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549 (2015).

    CAS  PubMed  Google Scholar 

  9. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Brentjens, R.J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817–4828 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Brentjens, R.J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).

    PubMed  PubMed Central  Google Scholar 

  12. Grupp, S.A. et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Davila, M.L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).

    PubMed  PubMed Central  Google Scholar 

  14. Lee, D.W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).

    CAS  PubMed  Google Scholar 

  15. Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

    PubMed  PubMed Central  Google Scholar 

  16. Brudno, J.N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112–1121 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Kochenderfer, J.N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129–4139 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Davila, M.L., Kloss, C.C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 8, e61338 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Ghosh, A. et al. PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer Res. 73, 4687–4696 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Ghosh, A. et al. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. J. Clin. Invest. 123, 2654–2662 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Bar, M. et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol. Blood Marrow Transplant. 19, 949–957 (2013).

    PubMed  Google Scholar 

  22. Srinivasan, M. et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119, 1570–1580 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Jacoby, E. et al. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood 127, 1361–1370 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Kochenderfer, J.N., Yu, Z., Frasheri, D., Restifo, N.P. & Rosenberg, S.A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875–3886 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Jenq, R.R. et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J. Exp. Med. 209, 903–911 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415–428 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Long, A.H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Hasan, M., Polic, B., Bralic, M., Jonjic, S. & Rajewsky, K. Incomplete block of B cell development and immunoglobulin production in mice carrying the μ MT mutation on the BALB/c background. Eur. J. Immunol. 32, 3463–3471 (2002).

    CAS  PubMed  Google Scholar 

  29. Rickert, R.C., Roes, J. & Rajewsky, K. B lymphocyte–specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25, 1317–1318 (1997).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Wherry, E.J. T cell exhaustion. Nat. Immunol. 12, 492–499 (2011).

    CAS  PubMed  Google Scholar 

  31. Teague, R.M. et al. Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity 28, 662–674 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Schietinger, A., Delrow, J.J., Basom, R.S., Blattman, J.N. & Greenberg, P.D. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335, 723–727 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Paley, M.A. et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338, 1220–1225 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15, 808–813 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Cruz, C.R. et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122, 2965–2973 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Small, T.N., Robinson, W.H. & Miklos, D.B. B cells and transplantation: an educational resource. Biol. Blood Marrow Transplant. 15 (Suppl. 1), 104–113 (2009).

    PubMed  PubMed Central  Google Scholar 

  37. Sayegh, M.H. et al. Allograft rejection in a new allospecific CD4+ TCR transgenic mouse. Am. J. Transplant. 3, 381–389 (2003).

    PubMed  Google Scholar 

  38. Schmaltz, C. et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat. Med. 8, 1433–1437 (2002).

    CAS  PubMed  Google Scholar 

  39. Rivière, I., Brose, K. & Mulligan, R.C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 92, 6733–6737 (1995).

    PubMed  Google Scholar 

  40. Lee, J., Sadelain, M. & Brentjens, R. Retroviral transduction of murine primary T lymphocytes. Methods Mol. Biol. 506, 83–96 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Zheng, Z., Chinnasamy, N. & Morgan, R.A. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J. Transl. Med. 10, 29 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Irizarry, R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).

    PubMed  Google Scholar 

  43. Smyth, G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article 3 (2004).

    Google Scholar 

Download references

Acknowledgements

We are thankful to M. Sayegh (Brigham and Women's Hospital and Children's Hospital Boston) for ABM mice, R. Negrin (Stanford University) for the A20-TGL cell line, E. Campeau (University of Massachusetts) for pENTR1A, D. Vignali (University of Pittsburgh Medical Center) for mouse TCR OTI-2A.pMIG II, and P. Khavari (Stanford University) for LZRS-Rfa plasmid. We appreciate the help of J. White, LCP, RARC, the flow cytometry core facility, the integrative genomics core, and the computational biology core at MSKCC. We also appreciate the help of H. Poeck in critical reading of the manuscript. This research was supported by National Institutes of Health award numbers R01-HL069929 (M.R.M.v.d.B.), R01-AI101406 (M.R.M.v.d.B.), P01-CA023766 (M.R.M.v.d.B.), and R01-AI100288 (M.R.M.v.d.B.), LLS (M. Sadelain), the Lymphoma Foundation, the Susan and Peter Solomon Divisional Genomics Program, MSKCC Cycle for Survival, and P30-CA008748 MSK Cancer Center Support Grant/Core Grant. A.G. is a fellow of the Lymphoma Research Foundation. M. Smith received funding from an NIH Diversity Supplement (PA-16-288) under R01-AI100288-08S1, the M.J. Lacher Research Fellowship (The Lymphoma Foundation), and the American Society for Blood and Marrow Transplantation New Investigator Award. M. Smith and S.J. are supported under an NIH T32 grant (T32-CA009207). S.J. is also a Young Investigator Awardee from the Conquer Cancer Foundation of ASCO. M.L.D. is supported by an ASH-AMFDP career development award, the Damon Runyon Fund, and K08-CA148821 (NCI). J.L.Z. is supported by LLS TRP grant 6465-15 and K08-CA160659 (NCI). A.Z.T. is supported by a grant from the Imaging and Radiation Sciences (IMRAS) Program of MSKCC. The content is solely the responsibility of the authors and does not represent the official views of the National Cancer Institute or the National Institutes of Health.

Author information

Authors and Affiliations

Authors

Contributions

A.G. and M.L.D. conceived the project. A.G., M. Smith, S.E.J., and M.L.D. contributed to the design of the experiments, supervised and conducted the experiments, generated the manuscript figures, and wrote the manuscript. E.V. and K.V.A. conducted the experiments and generated the manuscript figures. F.P. contributed to the performance of microarray analyses and interpretation of the data. A.C.F.M., G.F.M., and C.L. contributed to the performance of histological analyses and interpretation of the data. G.G., F.M.K., E.R.L., S.L., H.V.J., A.Z.T., L.T., L.F.Y., and K.T. assisted in conducting experiments. J.L.Z., J.A.D., R.R.J., A.M.H., and A.S. contributed to the design of the experiments and their analyses. M. Sadelain and M.R.M.v.d.B. supervised the project, contributed to the design of the experiments and their analyses, and wrote the manuscript.

Corresponding authors

Correspondence to Michel Sadelain or Marcel R M van den Brink.

Ethics declarations

Competing interests

M. Sadelain is a scientific cofounder of Juno Therapeutics. All other authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–9 (PDF 5829 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ghosh, A., Smith, M., James, S. et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med 23, 242–249 (2017). https://doi.org/10.1038/nm.4258

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.4258

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing